TY  - JOUR
AU  - Jara-Palomares, Luis
AU  - Solier-Lopez, Aurora
AU  - Elias-Hernandez, Teresa
AU  - Asensio-Cruz, Maribel
AU  - Blasco-Esquivias, Isabel
AU  - Marin-Barrera, Lucia
AU  - de la Borbolla-Artacho, Maria Rodriguez
AU  - Praena-Fernandez, Juan Manuel
AU  - Montero-Romero, Emilio
AU  - Navarro-Herrero, Silvia
AU  - Serrano-Gotarredona, Maria Pilar
AU  - Sánchez-Díaz, José María
AU  - Palacios, Carlos
AU  - Otero, Remedios
PY  - 2017
DO  - 10.1016/j.thromres.2017.07.004
UR  - http://hdl.handle.net/10668/11419
T2  - Thrombosis research
AB  - The safety and efficacy of low-molecular-weight heparin (LMWH) treatment in patients with cancer-associated thrombosis (CAT) beyond 6months are unknown. Our aim was to determine the safety of long-term tinzaparin use in patients with CAT. We performed...
LA  - en
KW  - Cancer
KW  - Low-molecular-weight heparin
KW  - Pulmonary embolism
KW  - Tinzaparin
KW  - Venous thromboembolism
KW  - Female
KW  - Fibrinolytic Agents
KW  - Heparin, Low-Molecular-Weight
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Neoplasms
KW  - Prospective Studies
KW  - Thrombosis
KW  - Time Factors
KW  - Tinzaparin
TI  - Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study.
TY  - research article
VL  - 157
ER  -